Background. The Pregnancy Registry for Varivax (Merck) was established to monitor for congenital varicella syndrome or other birth defects in the offspring of women who were exposed to varicella vaccine while pregnant.
Congenital varicella syndrome may occur in newborns of women who experience varicella disease after infection with wild-type varicella-zoster virus (VZV) during pregnancy [1, 2] . Congenital varicella syndrome is characterized by cutaneous scarring in a dermatome distribution and/or hypoplasia of an extremity [3] . Additional manifestations may include low birth weight, microcephaly, localized muscular atrophy, ocular anomalies, and neurological abnormalities [3] . The risk of congenital varicella syndrome is estimated to be ∼0.4% when maternal infection occurs from conception through the 12th week of gestation and 2% when infection occurs between the 13th and 20th week of gestation [2] . Case reports of newborns with defects Potential conflicts of interest: E.W., M.A.G., K.E.S., and R.G.S. are salaried employees at Merck and possess stock and stock options in the company. All other authors report no potential conflicts.
Financial support: supplement sponsorship is detailed in the Acknowledgments. consistent with congenital varicella syndrome have been described with infections as late as the 28th week of gestation [4, 5] .
Varivax (varicella virus vaccine live [Oka/Merck]) is a live, attenuated viral vaccine for the prevention of varicella disease. The vaccine is contraindicated during pregnancy, and it is recommended that pregnancy be avoided for 3 months [6] (Merck) or 1 month [7, 8] (Advisory Committee on Immunization Practices and American Academy of Pediatrics) after vaccination, because the effects of the vaccine on fetal development are not known. However, some women have inadvertently received varicella vaccine during pregnancy. To identify these women and to obtain information on the outcome of their pregnancies, a Pregnancy Registry for Varivax was established after licensure of the vaccine in 1995, as a collaborative effort between the Centers for Disease Control and Prevention and Merck. The objective of the registry is to examine whether exposure to varicella vaccine is associated with congenital varicella syndrome or an increased risk of other birth defects in offspring of women who inadvertently received varicella vaccine within 3 months before conception or any time during pregnancy. Review of data from the first 5 years of the pregnancy registry showed no offspring with congenital varicella syndrome born to women enrolled in the registry [9] . This article provides the updated data on 10 years of experience with reports to the pregnancy registry.
METHODS
Detailed methods for the pregnancy registry have been described elsewhere [9] . Briefly, the registry collects voluntary reports from health care providers or consumers about the pregnancy and offspring of women given varicella vaccine 3 months before, or at any time during, pregnancy. Health care providers are encouraged to enroll patients through inclusion of information about the pregnancy registry in the prescribing information for the product and on a dedicated Web site (http: //www.merckpregnancyregistries.com). Patients are enrolled in the registry if the following criteria are met: a health care provider is identified; there is a unique patient identifier to allow for follow-up (name, initials, chart number, or code); the exposure occurred in the United States, Puerto Rico, or Canada (from January 1999); and the exposure occurred within 3 months before or at any time during pregnancy. Pregnancy outcomes are ascertained from health care providers through questionnaires completed voluntarily and returned by mail or verbally by telephone. Since 1999, efforts have been made to obtain newborn and pediatric medical records. A patient or provider may decline to participate in the registry at any time.
Reports are classified by the timing of registry notification in relation to pregnancy outcome (prospective or retrospective), by VZV serostatus of the woman at the time of vaccination (seronegative, seropositive, or unknown), and by the timing of exposure to the first dose of vaccine in relation to gestational week of pregnancy from the last menstrual period (LMP) [9] . Prospective reports are those received before the outcome of the pregnancy is known, and retrospective reports are those received after the outcome of the pregnancy is known (including identification of a probable birth defect before delivery by diagnostic testing methods such as ultrasound). Only prospective reports are used to calculate outcome rates. To assess the risks by the timing of exposure, 3 potential risk periods are defined on the basis of known risks from wild-type VZV and biological plausibility: high risk (exposure during the first [0-13 weeks] or second [14-27 weeks] trimester of pregnancy), medium risk (exposure during the third trimester [28-42 weeks] or the month before LMP), and low risk (exposure 11 month before LMP).
The primary outcome of interest is congenital varicella syndrome; secondary outcomes include birth defects and pregnancy outcomes (i.e., live births, late fetal deaths, spontaneous abortions, and elective terminations). A late fetal death is defined as a death that occurs at у20 weeks of gestation [10] . Information on the analysis of the products of conception from fetal losses and elective terminations is routinely requested but rarely available. To identify birth defects that may have been missed at birth, pediatric medical records are requested for up to 2 years after birth for all newborns who have a signed maternal consent form. Birth defects are defined according to the CDC's Metropolitan Atlanta Congenital Defects Program (MACDP) guidelines [11] . Using MACDP methodology, the frequency of birth defects is measured as the prevalence at birth, expressed as the number of affected cases (live-born infants, fetal deaths, and terminations у20 weeks) with major birth defects per 100 live-born infants [12] . Because serological testing is not a requirement before vaccination, the majority of women enrolled in the registry received vaccine on the basis of a negative history of the disease. Studies have shown that the majority of US adults with negative or uncertain histories of disease are seropositive (range, 71%-93%) and, thus, are not at risk for infection [7] . Therefore, outcome rates for congenital varicella syndrome and birth defects are calculated using only data from women documented to be VZV seronegative before vaccination. Confidence intervals (CIs) are calculated using the Haenszel et al. [13] method for Poisson-distributed variables.
RESULTS

From 17 March 1995 through 16 March 2005
, the registry received 1432 reports of women with an exposure to varicella vaccine within 3 months before or at any time during pregnancy, and 981 (69%) of these patients were enrolled. Of the 944 enrolled patients with expected date of delivery before 17 March 2005, 894 (95%) exposures were reported prospectively, and 50 (5%) were reported retrospectively. The distribution of reports, shown in figure 1, resulted in 587 prospective reports and 46 retrospective reports being available for analysis.
Of the 587 women who were prospectively enrolled in the registry and who had outcomes available for analysis, 138 (24%) were VZV seronegative before vaccination, 440 (75%) were of unknown serological status, and 9 (1%) were seropositive. Of these 587 pregnancies, 523 (89%) resulted in 531 live-born infants (including 6 sets of twins and 1 set of triplets), 63 (11%) resulted in spontaneous abortions, and 1 resulted in a late fetal death. Fifty (79%) of the 63 spontaneous abortions occurred in the first trimester, and 7 (11%) occurred in the second trimester; for 6 (10%), there was no length of gestation reported. The fetal death occurred at ∼23 weeks of gestation. No infants were born with features consistent with congenital varicella syndrome among any of the women prospectively enrolled in the registry.
Among the 138 VZV-seronegative prospectively reported women, 129 (93%) gave birth to 131 live-born infants (including 2 sets of twins), and 9 (7%) had spontaneous abortions. More than half of these women (57%) had received the first dose of vaccine in the month immediately preceding or immediately after their LMP. Among the 131 live births, the prevalence rate of congenital varicella syndrome was 0% (95% CI, 0%-6.7%) (table 1) .
Eighty-nine (65%) VZV-seronegative women were vaccinated during the high-risk period (first or second trimester of pregnancy), and their pregnancies resulted in 82 (92%) live births and 7 (8%) first-trimester spontaneous abortions. Major birth defects were observed in 3 infants, 1 each with postaxial polydactyly, hypospadias, and a variant of tetralogy of Fallot, for a birth defect prevalence rate of 3.7% (95% CI, 0.8%-10.7%) (tables 1 and 2). One additional pregnancy in which exposure occurred during the high-risk period was electively terminated at 19 weeks after prenatal diagnosis of trisomy 21. Twenty-four VZV-seronegative women (18%) were vaccinated in the medium-risk period-1 in the third trimester, resulting in a live birth, and 23 in the month before LMP, resulting in 23 live births (1 set of twins) and 1 spontaneous abortion. No major birth defects were reported. One additional pregnancy in which exposure occurred during the medium-risk period was electively terminated at 18 weeks after prenatal diagnosis of hydrocephalus. Twenty-five VZV-seronegative women (18%) were vaccinated in the low-risk period (11 month before LMP); these pregnancies resulted in 25 live births and 1 spontaneous abortion. No major birth defects were reported.
Of the 449 prospectively reported women whose serostatus was positive or unknown, there were 394 pregnancies resulting in 400 live-born infants (including 4 sets of twins and 1 set of triplets). No features consistent with congenital varicella syndrome were reported among these infants. Birth defects identified in live birth pregnancy outcomes included hypospadias (2 infants) and polydactyly, atrial septal defect, unspecified dysmorphic syndrome, and renal dysplasia (1 infant each) (table 2). One pregnancy was electively terminated after prenatal diagnosis of trisomy 18 at 31 weeks of gestation. One report of a first-trimester spontaneous abortion in which the products of conception were examined identified the presence of trisomy 13. As mentioned above, 1 case of fetal death occurred at ∼23 weeks of gestation in a woman exposed 4 weeks after LMP; autopsy revealed no evidence of varicella-related lesions, results of culture for VZV were negative, and the cause of death was not determined [9] . Other conditions of the neonate that did not meet MACDP criteria as major birth defects were prospectively reported to the registry. They included 1 report each of "mild palpebral fissure asymmetry," hearing impairment, and preauricular sinuses (which was included as a major birth defect in the 5-year report but has been reclassified in accordance with MACDP methodology).
Among the 46 reports of women retrospectively enrolled in the registry and with outcomes available for analysis, 6 reports of birth defects were received, 1 of which was reported since the publication of the 5-year data (table 3). This report described renal agenesis in a late fetal death. The gestational age and timing of receipt of varicella vaccine was unknown. The other 5 defects, detailed in the previous publication, included 1 report each of left orbital roof defect with anophthalmia and encephalocele, trisomy 21, cystic hygroma and anasarca, holoprosencephaly, and unilateral renal dysplasia. As of 16 March 2005, there have been 22 instances in which the varicella vaccine was inadvertently administered in place of VZV immunoglobulin (VZIG) and 1 instance in which the vaccine was administered in place of a blood sample for varicella titer being drawn. Twenty-one cases were reported prospectively, and 2 were reported retrospectively (all included in the results presented above). Only 2 of the 23 reports were received since the 5-year report (March 2000). In one of these reports, the timing of vaccination was 25 weeks of gestation, and the live-born infant was reported to be healthy. The exposure and outcome data were not available for the second report. Among enrolled women with reports available, the timing of exposure ranged from gestational week 4 to week 34. All live-born infants ( ) from pregnancies reported prospectively ( ) n p 18 n p 15 were reportedly healthy, without birth defects (8 were born to VZV-seronegative mothers).
DISCUSSION
A decade of experience with reports to the Pregnancy Registry for Varivax show no cases with features consistent with congenital varicella syndrome in the cohort of women who received varicella vaccine during or shortly before pregnancy. However, the precision of this postlicensure surveillance study continues to be limited by the relatively small number of women known to be VZV seronegative, and, therefore, enrollment of exposed pregnant women will continue. Most exposures to varicella vaccine occurred in the month before or immediately after the LMP, either before conception or before women realized they were pregnant. Far fewer cases of product confusion between VZIG and varicella vaccine occurred in the second 5 years of the registry, compared with the first 5 years, which may reflect increased awareness of the problem [14, 15] with improved understanding of the differences between the products, decreased need for VZIG secondary to decreasing exposures to varicella among pregnant women, or both.
The prevalence of 3 major birth defects among infants born to VZV-seronegative women exposed to varicella vaccine in the highest-risk period, the first 2 trimesters of pregnancy, is similar to the reported prevalence rate in the general population (3.2% of live births/fetal death) [16] . These 3 major defects (postaxial polydactyly, hypospadias, and a variant of tetralogy of Fallot) are not related by morphology or by critical period of exposure and are, thus, unlikely to be associated with exposure to varicella vaccine. Two additional birth defects, trisomy 21 and hydrocephalus, identified by prenatal testing in VZV-seronegative mothers, do not appear to be morphologically related to the defects identified in the live-born infants. Considering all prospectively or retrospectively identified birth defects, the defects identified showed no specific pattern in either the susceptible cohort or the cohort as a whole. Among all prospective reports, there was 11 report of polydactyly (2 reports) and hypospadias (3 reports); however, for these defects, the timing of exposure differed. The rate of occurrence of these defects in this population is lower than or comparable to the background population rates for these events [17, 18] ; nevertheless, their occurrence will be closely monitored in the ongoing registry. The registry captured 1 retrospectively reported case of an ocular anomaly (anophthalmia). Ocular anomalies have been reported in cases of congenital varicella syndrome. However, this infant also had other defects, including an encephalocele (a neural tube defect), that are not consistent with features typically associated with congenital varicella syndrome. In addition, the infant had a negative result of a fluorescent antibody to membrane antigen test for varicella antibodies. In the prevaccine era, almost all women of childbearing age were immune to varicella (the probability of varicella susceptibility in US women of childbearing age was !5% [19] , with lower rates of immunity for women from Puerto Rico and other tropical areas) [20] . The susceptibility status is known for only a small proportion of women in the registry. However, because most women were vaccinated on the basis of negative or unknown disease history, which has low predictive value with respect to true susceptibility, the majority (∼80%) of women in the registry with unknown serostatus are likely to a Postaxial polydactyly type B is not considered to be a birth defect among black children, given its frequent occurrence in this group, but all types of polydactyly are considered to be birth defects among white children [18] .
be immune and their offspring not at risk for contracting congenital varicella syndrome [7] . However, since the start of the varicella vaccination program in the United States in 1995, there has been an 80%-90% decline in varicella cases. This decline has resulted in decreased opportunities for exposure [21] [22] [23] , which has the potential to increase the susceptibility of adolescents and young adults in their childbearing years unless they have been vaccinated. In 1999, the CDC Advisory Committee on Immunization Practices (ACIP) recommended vaccination of susceptible women of childbearing age [24] , and, in June 2005, the ACIP recommended routine screening during pregnancy for evidence of immunity to varicella and postpartum vaccination of women without such evidence [25] . Evidence of immunity in pregnant women includes history or laboratory diagnosis of varicella disease, age-appropriate vaccination, or serological evidence of immunity. Although for the general population, birth in the United States before 1980 is considered to be evidence of immunity, for pregnant women, birth before 1980 should not be considered to be evidence of immunity [25] . Postpartum vaccination of women without evidence of immunity need not be delayed because of breastfeeding [25] , because varicella vaccine has not been demonstrated to be secreted in breast milk [26, 27] . A study involving 12 women who received varicella vaccine while breastfeeding showed no evidence of VZV DNA in a total of 217 breast milk samples collected or in the infants tested after both vaccine doses [26] ; in addition, no infants seroconverted. The small sample size of VZV-seronegative women continues to be a limitation for the precision of the 95% CI around the 0% prevalence rate for congenital varicella syndrome. Other limitations include voluntary notification (subject to reporting bias and undernotification), incomplete detection of birth de- 
NOTE.
There was 1 additional retrospective birth defect report of "lesions on the brain" that did not contain any additional information to allow further evaluation. LMP, last menstrual period; NR, not reported; VZV, varicella-zoster virus.
fects, underrepresentation of spontaneous abortions and elective terminations, and the unknown serostatus of the majority of women enrolled in the registry [9] .
Although the numbers of exposures are not sufficient to rule out a very low risk, data collected in the pregnancy registry to date do not support a relationship between the occurrence of congenital varicella syndrome or other birth defects and varicella vaccine exposure during pregnancy. Varicella vaccine is contraindicated in pregnancy. At the time of vaccination, women of reproductive age need to be reminded to avoid pregnancy for an interval of 1-3 months after vaccination [6] [7] [8] . Physicians and other health care providers should remember to question all women of childbearing age about the possibility of pregnancy before administering any vaccination, and those providing prenatal care should screen all women for evidence of immunity during pregnancy and offer vaccine to susceptible women after delivery. Health care professionals are encouraged to continue to enroll patients who inadvertently receive the varicella vaccine into the pregnancy registry by calling 800-986-8999. Enrollment forms are available on the Web site (http:// www.merckpregnancyregistries.com).
